References
- 1. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999-1009.
- 2. Maeng M, Tilsted HH, Jensen LO, et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORTOUT III study): a multicentre, open-label, randomised superiority trial. Lancet. 2014;383:2047-2056.
- 3. Stone GW, Gao R, Kimura T, et al. 1-Year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277-1289.
- 4. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
- 5. Benedek T, Bucur O, Pașcanu I, Benedek I. Analysis of coronary plaque morphology by 64 multislice computed tomography coronary angiography and calcium scoring in patients with type 2 diabetes mellitus. Acta Endocrinologica. 2011;7:59-68.
- 6. Benedek I, Chitu M, Kovacs I, Bajka B, Benedek T. Incremental Value of preprocedural Coronary Computed Tomographic Angiography to classical Coronary Angiography for prediction of PCI complexity in left main stenosis. World Journal of Cardiovascular Disease. 2013;9:573-580.
- 7. Benedek T, Jako B, Benedek I. Plaque quantification by coronary CT and intravascular ultrasound identifies a low CT density core as a marker of plaque instability in acute coronary syndromes. Int Heart J. 2014:55:22-28.
- 8. Benedek T, Gyongyosi M, Benedek I. Multislice computed tomographic coronary angiography for quantitative assessment of culprit lesions in acute coronary syndromes. Can J Cardiol. 2013;29:364-371.
- 9. Gogas BD, Serruys PW, Diletti R, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimuseluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. JACC Cardiovasc Interv. 2012;5:656-665.
- 10. Verheye S, Martinet W, Kockx MM, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-715.
- 11. Ferent IF, Mester A, Hlinomaz O, et al. Intracoronary Imaging for Assessment of Vascular Healing and Stent Follow-up in Bioresorbable Vascular Scaffolds. Current Medical Imaging Reviews. 2018. [E-pub ahead of print.] doi: 10.2174/1573405614666180604093621.10.2174/1573405614666180604093621
- 12. Fajadet J, Haude M, Joner M, et al. Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. EuroIntervention. 2016;12:828-833.
- 13. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144-1153.
- 14. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-797.
- 15. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. 2011;4:535-538.
- 16. Bourantas CV, Garcia-Garcia HM, Diletti R, Muramatsu T, Serruys PW. Early detection and invasive passivation of future culprit lesions: a future potential or an unrealistic pursuit of chimeras? Am Heart J. 2013;165:869-881.
- 17. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012;33:1325-1333.
- 18. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221:106-112.
- 19. Gomez-Lara J, Brugaletta S, Farooq V, et al. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv. 2011;4:789-799.
- 20. Lane JP, Perkins LE, Sheehy AJ, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv. 2014;7:688-695.
- 21. Serruys PW, Onuma Y. Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS? EuroIntervention. 2017;12:2047-2056.
- 22. James SK, Stenestrand U, Lindback J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 2009;360:1933-1945.
- 23. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
- 24. Serruys PW, Daemen J. The SCAAR registry or the Swedish yo-yo. EuroIntervention. 2007;3:297-300.